BioCryst culls Fac­tor D in­hibitor; El­e­va­tion On­col­o­gy’s stock plum­mets

Plus, news about Tenax Ther­a­peu­tics:

BioCryst dis­con­tin­ues Fac­tor D in­hibitor: This is af­ter find­ing that “clin­i­cal ac­tiv­i­ty ob­served was less than oth­er ther­a­pies on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER